Figure 6.
HOXA10-AS downregulation impairs leukemic growth in vivo. (A) Experimental design for HOXA10-AS knockdown in vivo in a patient-derived xenograft (PDX) model of AML. (B) PDX engraftment levels (dTomato+ or GFP+) in the bone marrow (BM), spleen (Sp), and liver (Li) in recipient mice after leukemia onset, displayed as percentage of transduced human CD45+ cells (right; unpaired Student t test). Representative FACS plots (left) of the bone marrow show the gating strategy to assess the percentage of fluorescent cells. NSG, NOD.Cg-PrkdcscidIl2rgtm1Wjl /SzJ; SSC, side scatter.

HOXA10-AS downregulation impairs leukemic growth in vivo. (A) Experimental design for HOXA10-AS knockdown in vivo in a patient-derived xenograft (PDX) model of AML. (B) PDX engraftment levels (dTomato+ or GFP+) in the bone marrow (BM), spleen (Sp), and liver (Li) in recipient mice after leukemia onset, displayed as percentage of transduced human CD45+ cells (right; unpaired Student t test). Representative FACS plots (left) of the bone marrow show the gating strategy to assess the percentage of fluorescent cells. NSG, NOD.Cg-PrkdcscidIl2rgtm1Wjl /SzJ; SSC, side scatter.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal